CELL INTELLIGENCE · 肿瘤细胞治疗研究

BTK 抑制剂在初治和复发/难治性套细胞淋巴瘤中的疗效比较：系统综述和荟萃分析

Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis.

CAR-T 细胞对比双特异性抗体治疗复发/难治性套细胞淋巴瘤：系统综述与荟萃分析

CAR T-cell vs bispecific antibodies in relapsed/refractory mantle cell lymphoma: a systematic review and meta-analysis.

CAR-T 细胞疗法相比双特异性抗体显示出更高的 CR 率，支持其作为 R/R MCL 有效三线治疗的作用。需要随机试验来证实这些发现。

Mosunetuzumab 联合 polatuzumab vedotin 治疗 BTK 抑制剂治疗后的复发/难治性 MCL：一项 2 期研究

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Mosunetuzumab：一种用于滤泡性淋巴瘤的双特异性 CD20 × CD3 抗体，在其他 B-NHL 亚型中具有良好前景

Mosunetuzumab: A bispecific CD20 × CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes.

老年套细胞淋巴瘤：生物学风险分层、体能适应性策略与未满足需求

Mantle Cell Lymphoma in Geriatric Patients: Biologic Risk Stratification, Fitness-Adapted Strategies, and Unmet Needs.

套细胞淋巴瘤的现代管理

Modern Management of Mantle Cell Lymphoma.

relmacabtagene autoleucel（CD19 CAR-T）治疗中国成人复发/难治性套细胞淋巴瘤的 2 期研究

Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults.

双特异性抗体联合方案治疗 B 细胞非霍奇金淋巴瘤

Bispecific antibody combination regimens for B-cell non-Hodgkin's lymphomas.

BsAb 代表 B-NHL 治疗的一大进步，可提供高比例的深度缓解，且安全性可预测、适合门诊使用。随着试验数据不断成熟，基于 BsAb 的方案有望成为多线治疗的基础，重塑对侵袭性和惰性淋巴瘤患者的预期。

非霍奇金淋巴瘤免疫治疗新进展：让 T 细胞参与抗癌之战

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

复发/难治性套细胞淋巴瘤的 T 细胞重定向免疫治疗：当前证据、序贯治疗与未来方向

T-Cell-Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions.